Balancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy.
作者信息
Montini Eugenio, Naldini Luigi, Booth Claire, Kohn Donald B, Aiuti Alessandro
机构信息
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) IRCCS San Raffaele Scientific Institute, Milan, Italy.
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita - Salute San Raffaele University Medical School, Milan, Italy.
出版信息
Mol Ther. 2025 Jan 8;33(1):6-8. doi: 10.1016/j.ymthe.2024.12.028. Epub 2024 Dec 26.
Abstract
摘要
相似文献
1
Balancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy.在慢病毒载体介导的造血干细胞基因治疗中平衡疗效与安全性
Mol Ther. 2025 Jan 8;33(1):6-8. doi: 10.1016/j.ymthe.2024.12.028. Epub 2024 Dec 26.
2
Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations.临床前慢病毒造血干细胞基因治疗纠正庞贝病相关的肌肉和神经表现。
Mol Ther. 2024 Nov 6;32(11):3847-3864. doi: 10.1016/j.ymthe.2024.09.024. Epub 2024 Sep 17.
3
Lentiviral Vector-Mediated Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model.慢病毒载体介导的造血干细胞基因治疗黏多糖贮积症 IVA 小鼠模型。
Hum Gene Ther. 2024 Nov;35(21-22):917-937. doi: 10.1089/hum.2024.094. Epub 2024 Oct 24.
4
Hematopoietic stem cell gene therapy improves outcomes in a clinically relevant mouse model of multiple sulfatase deficiency.造血干细胞基因疗法改善了多重硫酸酯酶缺乏症临床相关小鼠模型的治疗效果。
Mol Ther. 2024 Nov 6;32(11):3829-3846. doi: 10.1016/j.ymthe.2024.08.015. Epub 2024 Aug 22.
5
Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells.一种tCD25预选择性联合抗HIV慢病毒载体在人造血干细胞和祖细胞中的安全性和有效性。
Stem Cells. 2015 Mar;33(3):870-9. doi: 10.1002/stem.1919.
6
B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.威斯科特-奥尔德里奇综合征患者经慢病毒载体介导的基因治疗后的B细胞重建
J Allergy Clin Immunol. 2015 Sep;136(3):692-702.e2. doi: 10.1016/j.jaci.2015.01.035. Epub 2015 Mar 16.
7
Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.用三重组合抗 HIV 慢病毒载体转导的 CD34(+)造血干细胞生成抗 HIV-1 免疫系统。
J Virol. 2012 May;86(10):5719-29. doi: 10.1128/JVI.06300-11. Epub 2012 Mar 7.
8
Preclinical development of lentiviral vector gene therapy for Diamond-Blackfan anemia syndrome.用于先天性纯红细胞再生障碍性贫血综合征的慢病毒载体基因治疗的临床前开发。
Mol Ther. 2025 Jul 2;33(7):3086-3100. doi: 10.1016/j.ymthe.2024.12.020. Epub 2024 Dec 12.
9
The Engraftment of Lentiviral Vector-Transduced Human CD34+ Cells into Humanized Mice.慢病毒载体转导的人CD34+细胞植入人源化小鼠体内。
Methods Mol Biol. 2019;2005:91-100. doi: 10.1007/978-1-4939-9524-0_7.
10
Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.慢病毒造血干细胞/祖细胞基因疗法治疗威斯科特-奥尔德里奇综合征：一项非随机、开放标签的1/2期临床研究的中期结果。
Lancet Haematol. 2019 May;6(5):e239-e253. doi: 10.1016/S2352-3026(19)30021-3. Epub 2019 Apr 10.
引用本文的文献
1
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy.用于基因治疗的造血干细胞和祖细胞的体外修饰
Mol Ther. 2025 May 7;33(5):2141-2153. doi: 10.1016/j.ymthe.2025.03.058. Epub 2025 Apr 1.
2
Safety and efficacy of gene therapy for RAG1-deficient SCID.RAG1缺陷型重症联合免疫缺陷病基因治疗的安全性和有效性。
Mol Ther. 2025 May 7;33(5):1869-1870. doi: 10.1016/j.ymthe.2025.02.044. Epub 2025 Mar 18.
本文引用的文献
1
Long-term lineage commitment in haematopoietic stem cell gene therapy.造血干细胞基因治疗中的长期谱系定向分化
Nature. 2024 Dec;636(8041):162-171. doi: 10.1038/s41586-024-08250-x. Epub 2024 Oct 23.
2
Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy.权衡慢病毒基因疗法治疗脑肾上腺脑白质营养不良的风险
N Engl J Med. 2024 Oct 10;391(14):1358-1359. doi: 10.1056/NEJMe2409399.
3
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy.脑肾上腺脑白质营养不良基因治疗后的血液系统癌症。
N Engl J Med. 2024 Oct 10;391(14):1287-1301. doi: 10.1056/NEJMoa2405541.
4
Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy.基因工程与造血干细胞生物学相遇，开启下一代基因治疗的新篇章。
Cell Stem Cell. 2023 May 4;30(5):549-570. doi: 10.1016/j.stem.2023.04.014.
5
Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency.慢病毒载体隐秘剪接介导人 X 连锁严重联合免疫缺陷中表达截短 HMGA2 的 CD34+ 克隆增加。
Nat Commun. 2022 Jun 28;13(1):3710. doi: 10.1038/s41467-022-31344-x.
6
Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.镰状细胞病基因治疗后发生的急性髓系白血病病例。
N Engl J Med. 2022 Jan 13;386(2):138-147. doi: 10.1056/NEJMoa2109167. Epub 2021 Dec 12.
7
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.基因治疗镰状细胞病后的白血病：插入突变，白消安，还是两者都不是。
Blood. 2021 Sep 16;138(11):942-947. doi: 10.1182/blood.2021011488.
8
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.腺苷脱氨酶严重联合免疫缺陷症的基因治疗后的长期结果。
Blood. 2021 Oct 14;138(15):1304-1316. doi: 10.1182/blood.2020010260.
9
Gene therapy using haematopoietic stem and progenitor cells.利用造血干细胞和祖细胞进行基因治疗。
Nat Rev Genet. 2021 Apr;22(4):216-234. doi: 10.1038/s41576-020-00298-5. Epub 2020 Dec 10.
10
Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.揭示和剖析自失活慢病毒载体在体内的遗传毒性。
Mol Ther. 2014 Apr;22(4):774-85. doi: 10.1038/mt.2014.3. Epub 2014 Jan 20.
Zotero 插件